CLIMB BIO, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
CLIMB BIO, INC. (CLYM) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $0 as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2024-03-28
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $3.50M.
- 2023-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $15.71M.
- 2022-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $18.59M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 |
| 2023-06-30 | $3.50M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $15.71M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $18.59M 10-K · filed 2024-03-28 |
| 2022-09-30 | $16.50M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |